|Bid||385.80 x 800|
|Ask||386.17 x 2200|
|Day's Range||380.97 - 386.55|
|52 Week Range||158.71 - 450.93|
|PE Ratio (TTM)||107.64|
|Earnings Date||Oct 24, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||449.11|
CNBC's Bob Pisani reports on the bull run, including the biggest performers and laggards. With CNBC's Michelle Caruso-Cabrera and the Fast Money traders, Tim Seymour, Brian Kelly, Steve Grasso and Guy Adami.
DANVERS, Mass., Sept. 19, 2018-- Abiomed, Inc., the leader in heart recovery, announces its initiatives at the 30th Transcatheter Cardiovascular Therapeutics conference will highlight the recently expanded ...
In case you’ve forgotten, after the financial meltdown, it was dividend stocks that were the ‘new’ growth stocks. With that in mind, the following are seven tech stocks sport high growth reminiscent of Amazon.com, Inc. (NASDAQ:AMZN) that you may not have seen in many headlines.
Easily the biggest trend in investing has to be healthcare stocks. From rising and aging populations in the developed world to new middle-class consumers gaining access to healthcare for the first time in emerging markets, healthcare demand is only getting bigger by the day. All in all, the combination of the two factors makes the medical device stocks some of best plays in all of healthcare.
Abiomed (ABMD), which is focused on native heart recovery with its Impella line of devices, has reported a 103.6% YTD (year-to-date) rise in the stock, from $192.49 on January 2, 2018, to $377.49 on September 7, 2018.
ABIOMED Inc (NASDAQ:ABMD), a large-cap worth US$17.23b, comes to mind for investors seeking a strong and reliable stock investment. Most investors favour these big stocks due to their strong balanceRead More...
How Do Abiomed’s Valuations Look in September? Wall Street analysts estimate Abiomed (ABMD) will report 29.9% growth in revenues to ~$771.0 million in 2019 as compared to $593.7 million in 2018. The earnings per share are expected to be $4.66 in 2019.
As discussed earlier, Abiomed (ABMD) reported revenues of $180.0 million in Q1 2019, a 36% increase as compared to revenues of ~$132.5 million in the first quarter of 2018.
Abiomed (ABMD) is a leading medical devices company. Its revenues rose 36% YoY to ~$180 million in fiscal Q1 2019 compared to $133 million in Q1 2018. The chart below compares revenues and EPS for Abiomed since the first quarter of 2018.
In this wide-ranging interview, Fool contributor Brian Feroldi chats with CEO Michael Minogue about the medical device company's competitive landscape, growth potential, valuation, and more.
Advanced Micro Devices is the hottest stock of the year. One technician sees the possibility of a move back to levels not seen since June 2006.
Interest rates are below the magic 3% number, earnings are strong, unemployment is low and the economy just came off its best quarter in 4 years.